IRMD - CIK 0001325618
The table below shows IRADIMED CORP's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $24.95M | $25.62M | $13.47M | $10.04M | $11.26M | $5.82M |
| Capital expenditure | $7.76M | $8.01M | $7.44M | $823.02K | $482.32K | $443.00K |
| Investing cash flow | -$8.42M | -$8.82M | -$8.01M | -$1.37M | $648.24K | $246.97K |
| Dividends paid | $15.04M | $13.68M | $13.22M | $12.56M | - | - |
IRADIMED CORP reported operating cash flow of $24.95M for fiscal year 2025. That is down 2.6% from $25.62M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $9.41M (FY 2016) to $24.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$17.60M | -$14.34M | -$13.66M | -$12.71M | $24.43K | $522.48K |